title: [The effect of pitavastatin on blood glucose and its efficacy in diabetic patients with hypercholesterolemia].
abstract: OBJECTIVE
  To evaluate the effect of pitavastatin on blood glucose in patients with hypercholesterolemia, and to investigate the efficacy of pitavastatin in diabetic patients combined with hypercholesterolemia.
  
  
  METHODS
  This study was a 12-week, multi-center, open-label, without parallel-group comparison, phase IV clinical trail.
  
  
  RESULTS
  Contrasting to baseline, the prevalences at week 4 and 12 post-treatment of abnormal fasting plasma glucose (FPG) and glycosylated hemoglobin A1c (HbA1c) (FPG: 14.2%vs 14.1% and 11.0%; HbA1c: 14.3% vs 15.1% and 16.1%) in the safety set subjects without diabetes mellitus (DM), as well as in those with DM but not taking glucose-lowering drugs (FPG: 7/7 vs 4/7 and 5/7; HbA1c: 5/5 vs 4/4 and 5/5) had no significant changes (all P values > 0.05). Contrasting to baseline, the levels of TC [(6.51 ± 0.94) mmol/L vs (5.12 ± 0.93) mmol/L and (4.54 ± 1.00) mmol/L], LDL-C [(4.11 ± 0.79) mmol/L vs (3.02 ± 0.81) mmol/L and (2.51 ± 0.70) mmol/L] and TG [2.10 (1.53, 2.54) mmol/L vs 1.62 (1.26, 2.00) mmol/L and 1.35 (1.10, 1.86) mmol/L]at week 4 and 12 post-treatment in the per protocol set 55 subjects with DM were significantly reduced (all P values < 0.05); 33.3% of subjects at high risk and 10.0% of subjects at very high risk had achieved a TC target value; 55.6% of subjects at high risk and 40.0% of subjects at very high risk had achieved a LDL-C target value.
  
  
  CONCLUSIONS
  Pitavastatin has a safe effect on blood glucose and it could be used to treat diabetic patients combined with hypercholesterolemia in China.
authors.affiliation: Fudan University, Shanghai, China. jmy@fudan.edu.cn
authors.forename: Yong
authors.initials: Y
authors.lastname: Mao
authors.forename: Jin-ming
authors.initials: JM
authors.lastname: Yu
authors.forename: Fen
authors.initials: F
authors.lastname: Zhang
authors.forename: Da-yi
authors.initials: DY
authors.lastname: Hu
authors.forename: Rong-jing
authors.initials: RJ
authors.lastname: Ding
authors.forename: Yi-qiang
authors.initials: YQ
authors.lastname: Zhan
authors.forename: She-chang
authors.initials: SC
authors.lastname: Li
authors.forename: Qun-yu
authors.initials: QY
authors.lastname: Kong
authors.forename: Fan-li
authors.initials: FL
authors.lastname: Lin
authors.forename: Gong-xian
authors.initials: GX
authors.lastname: Jia
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D011804:Quinolines; C108475:pitavastatin